Navigation Links
FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System
Date:6/20/2011

SILVER SPRING, Md., June 20, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today issued draft guidance that will help advance the development and approval of an artificial pancreas system to treat type 1 diabetes in the United States.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Type 1 diabetes is a chronic condition in which the pancreas produces little or no insulin, a hormone needed to properly control blood glucose (sugar) levels. Without enough insulin, glucose builds up in the bloodstream instead of going into the cells.

People with type 1 diabetes must regulate their blood glucose levels by checking their levels with a glucose meter multiple times daily, calculating how much insulin is needed to lower their blood glucose levels, and administering the necessary dose using a syringe or insulin pump.

An artificial pancreas system is an automated, closed-loop system that combines a continuous glucose monitor, an insulin infusion pump, and a glucose meter for calibrating the monitor. The devices are designed to work together, monitoring the body's glucose levels and automatically pumping appropriate doses of insulin as determined by a computer algorithm.

Today's draft guidance document addresses an early version of an artificial pancreas system, known as a Low Glucose Suspend system.  The Low Glucose Suspend system can help reduce or lessen the severity of a dangerous drop in glucose levels (hypoglycemia) by temporarily reducing or stopping the delivery of insulin. However, patients must still manage their glucose levels with a glucose meter and give themselves insulin, if necessary. The draft guidance provides recommendations for those planning to develop and submit an application for a Low Glucose Suspend (LGS) system intended for single patient use in the home environment.  

The FDA is seeking input from industry, researchers, the clinical community, and other stakeholders on the draft Low Glucose Suspend guidance. Specifically, the agency is interested in the types of clinical studies that should be conducted and what their target outcomes should be to demonstrate safety and effectiveness, necessary requirements for FDA approval.

"Our goal is to provide a clear pathway for artificial pancreas development so that people with diabetes can benefit from innovative medical devices," said Jeffrey Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health. "Getting a safe and effective artificial pancreas system to Americans with type 1 diabetes is an FDA priority."

The FDA currently is working on a second draft guidance that will help manufacturers and researchers develop more autonomous artificial pancreas systems. That guidance is expected to be issued by the end of the year.

For more information:

Draft Guidance http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm259301.htm

FDA: Artificial Pancreas Systems

http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/HomeHealthandConsumer/ConsumerProducts/ArtificialPancreas/default.htm

FDA: Medical Devices

http://www.fda.gov/MedicalDevices/default.htm

CDC:  Centers for Disease Control and Prevention—Diabetes Public Health Resource

http://www.cdc.gov/diabetes/

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Karen Riley, 301-796-4674, karen.riley@fda.hhs.gov

Consumer Inquiries: 1-888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
2. United Kingdoms National Institute for Health and Clinical Excellence Issues Guidance on Percutaneous Tibial Nerve Stimulation for Faecal Incontinence
3. BD Issues 2010 Sustainability Report
4. MedImmune To Present Eight Abstracts on Projects Regarding Thoracic and Respiratory Issues at the Annual American Thoracic Society International Conference
5. FDA Issues Final Guidance for Liquid OTC Drug Products With Dispensing Devices
6. Dehaier Medical Chairman and CEO Issues Letter to Shareholders
7. Omni Bio Pharmaceutical, Incs. CEO Issues Letter to Shareholders
8. The Centers For Medicare and Medicaid Services Issues Advance Guidance to Part D Plan Sponsors Allowing the Use of Generic Sampling as Medicare Part D Drug Utilization Management Tool.
9. New FDLIs Food and Drug Policy Forum Focuses on Liability Issues in Vaccine Design Defect Claims
10. UBM TechInsights Issues Warning to Medical Devices Industry About Possible Obsolescence as Reliance on Smartphones Increases
11. Qualitest Pharmaceuticals Issues Voluntary, Nationwide Recall of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg / 500 mg, NDC 0603-3888-20, 60 Count, Lot Numbers T150G10B, T120J10E and T023M10A and Phenobarbital Tablets, USP 32.4 mg, ND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 Global Cervical Dysplasia Market: Scope ... cervical dysplasia market analyzes the current and future ... elaborate executive summary, including a market snapshot that ... The research is a combination of primary ... of our research efforts along with information collected ...
(Date:12/7/2016)... Research and Markets has announced the addition ... Global Forecast to 2021" report to their offering. ... , , The ... growing at a CAGR of 7.3% during the forecast period of 2016 ... cancer and rapidly increasing geriatric population across the globe are the primary ...
(Date:12/7/2016)... Dec. 7, 2016  Palatin Technologies, Inc. ("Palatin") ... on a previously disclosed underwritten public offering of ... acted as sole book-running manager, Roth Capital Partners ... acted as co-manager for the offering. ... in net proceeds, allowing us to continue advancing ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... , ... California Senate Bill (SB) 863, signed into law in 2012, may ... 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a study ... medical payments per claim in California decreased 4 percent in 2013 and then 3 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Dickinson Insurance ... offices headquartered in Little Rock, has initiated a charity drive to provide support ... Foundation to End Senior Hunger, Arkansas ranks first in senior hunger statewide, third ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Coppin Insurance ... owners and families in and around the Cape Coral area, is embarking on a ... Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest Florida ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again ... that it is one of the early adopters completing EU-U.S. Privacy Shield Certification from ... to provide companies on both sides of the Atlantic with a mechanism to comply ...
Breaking Medicine News(10 mins):